Abstract
ObjectiveThe purpose of this study was to compare imaging features between COVID-19 and mycoplasma pneumonia (MP).Materials and methodsThe data of patients with mild COVID-19 and MP who underwent chest computed tomography (CT) examination from February 1, 2020 to April 17, 2020 were retrospectively analyzed. The Pneumonia-CT-LKM-PP model based on a deep learning algorithm was used to automatically quantify the number, volume, and involved lobes of pulmonary lesions, and longitudinal changes in quantitative parameters were assessed in three CT follow-ups.ResultsA total of 10 patients with mild COVID-19 and 13 patients with MP were included in this study. There was no difference in lymphocyte counts at baseline between the two groups (1.43 ± 0.45 vs. 1.44 ± 0.50, p = 0.279). C-reactive protein levels were significantly higher in MP group than in COVID-19 group (p < 0.05). The number, volume, and involved lobes of pulmonary lesions reached a peak in 7–14 days in the COVID-19 group, but there was no peak or declining trend over time in the MP group (p < 0.05).ConclusionBased on the longitudinal changes of quantitative CT, pulmonary lesions peaked at 7–14 days in patients with COVID-19, and this may be useful to distinguish COVID-19 from MP and evaluate curative effects and prognosis.
Highlights
Coronavirus Disease-19 (COVID-19) is a highly infectious lung disease caused by a novel coronavirus
It is possible for a radiologist to diagnose COVID-19 through computed tomography (CT) manifestations of bilateral ground glass opacity (GGO) and/or consolidation [3], a diagnosis of COVID-19 based on imaging may
Participants A total of 10 patients with mild type COVID-19 and 13 patients with suspected COVID-19 who were diagnosed with mycoplasma pneumonia (MP) were enrolled in this study
Summary
Coronavirus Disease-19 (COVID-19) is a highly infectious lung disease caused by a novel coronavirus. On February 11, 2020, the International Virus Classification Committee officially named the novel coronavirus as "SARS-CoV-2." The World Health Organization termed the new coronavirus pneumonia as COVID-19 [1]. The diagnosis of COVID-19 depends on nucleic acid detection, but the sensitivity is not high, and there are many false negatives. High-resolution computed tomography (HRCT) screening can detect early lung changes in patients with COVID-19 and provide more diagnostic information [2]. It is possible for a radiologist to diagnose COVID-19 through CT manifestations of bilateral ground glass opacity (GGO) and/or consolidation [3], a diagnosis of COVID-19 based on imaging may. Liu et al BMC Medical Imaging (2022) 22:21 be incorrect because many other diseases can exhibit similar patterns. In view of the different infectivity and treatments, it is crucial to accurately differentiate COVID-19 patients who need to be isolated and treated as soon as possible from MP patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
